Organization | Research Institute of Fundamental and Clinical Immunology

Research Institute of Fundamental and Clinical Immunology Report issue

Academic/Hospital Phase 1

Organization Overview

First Clinical Trial

2014

NCT03113019

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2016

Timeline

NOW

Now

Alternative names

Research Institute of Fundamental and Clinical Immunology | RIFCI

Active Ingredients

Drugs in Phase 1 Trials (2)

autologous dendritic cells loaded with autologous tumor lysate (1 trial)

dendritic cells (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 1)

Colorectal Neoplasms (Phase 1)

Overview

Highest Phase: Phase 1
# of Trials: 2
# of Trial APIs: 2